World Pharma News Digest - 02.06.2014
4 views
Skip to first unread message
Ruslan David
Jun 2, 2014, 5:54:26 AM6/2/14
to worldph...@googlegroups.com
'Quadrapeutics' works in preclinical study of hard-to-treat tumors
The first preclinical study of a new Rice University-developed anti-cancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells - often by blowing them apart - without harming surrounding normal organs. The research, which is available online this week Nature Medicine, reports that Rice's "quadrapeutics" technology was 17 times more efficient than conventional chemoradiation therapy against aggressive, drug-resistant head and neck tumors.
Read more...
http://www.worldpharmanews.com/research/2790-quadrapeutics-works-in-preclinical-study-of-hard-to-treat-tumors
Pfizer and the Avon Foundation for Women announce $1 million grants program
Despite the high level of public attention devoted to breast cancer awareness, more than 60 percent of respondents in a new national survey commissioned by Pfizer Inc. say they know little to nothing about metastatic breast cancer.(1) The survey is the first of its kind to examine the general public's understanding of metastatic breast cancer, which affects up to 250,000 women and men in the U.S. today.(2)
Read more...
http://www.worldpharmanews.com/pfizer/2789-pfizer-and-the-avon-foundation-for-women-announce-1-million-grants-program
Understanding and overcoming a novel type of anticancer drug resistance
A mechanism that enables the development of resistance to Acute Myeloid Leukemia (AML) anticancer drugs, thereby leading to relapse, has been identified by Katherine Borden of the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) and her collaborators. Katherine Borden is a Principal Investigator at IRIC and a professor at the university's Department of Pathology and Cell Biology.
Read more...
http://www.worldpharmanews.com/research/2788-understanding-and-overcoming-a-novel-type-of-anticancer-drug-resistance
Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS
In support of World MS Day, Novartis announced today the launch of the 7-Day Challenge to Live Like You for people with MS. The 7-Day Challenge to Live Like You, one of the first integrations of emerging technological trends by a pharmaceutical company, is simple: using wearable technology or accessing personal online systems that people use on a daily basis, including calendars, social media channels and fitness trackers, people with MS are invited to track their activities for seven days and gain valuable insights into what works best for their lifestyle.
Read more...
http://www.worldpharmanews.com/novartis/2787-novartis-launches-7-day-challenge-to-live-like-you-enabling-people-with-ms-to-better-understand-their-lives-with-ms
FDA approves many drugs that predictably increase heart and stroke risk
The agency charged to protect patients from dangerous drug side effects needs to be far more vigilant when it comes to medications that affect blood pressure. Robert P. Blankfield, MD, MS, a clinical professor of family medicine, issues this call to the U.S. Food and Drug Administration (FDA) in an editorial published recently in an online edition of the Journal of Cardiovascular Pharmacology and Therapeutics; the print version of the article is expected to appear this autumn.
Read more...
http://www.worldpharmanews.com/research/2786-fda-approves-many-drugs-that-predictably-increase-heart-and-stroke-risk
Pfizer brings frequent heartburn relief OTC with new Nexium® 24HR
Pfizer Inc. (NYSE: PFE) has announced the introduction in the U.S. of over-the-counter (OTC) Nexium®24HR, making The Purple Pill® available for the treatment of frequent heartburn (two or more days a week) in adults (18 years and older). Heartburn affects more than 60 million men and women in the United States at least once a month with 15 million Americans suffering from it daily.(1)
Read more...
http://www.worldpharmanews.com/pfizer/2785-pfizer-brings-frequent-heartburn-relief-otc-with-new-nexiumr-24hr
New way to treat HER2-positive breast cancer
Scientists at Cold Spring Harbor Laboratory (CSHL) have reported a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer. The breast cancer subtype in question is commonly called "HER2-positive"; it's a subset of the disease affecting about one patient in four, in which tumor cells overexpress a signaling protein called HER2.
Read more...
http://www.worldpharmanews.com/research/2784-new-way-to-treat-her2-positive-breast-cancer
PharmaNews.eu / Latest News
Finnish researchers discovered a new anticancer compound using accelerated drug screening process
http://www.pharmanews.eu/research-and-development/1446-finnish-researchers-discovered-a-new-anticancer-compound-using-accelerated-drug-screening-process
Biovision presents its selection of 44 promising life sciences businesses and projects
http://www.pharmanews.eu/conferences-and-events/1445-biovision-presents-its-selection-of-44-promising-life-sciences-businesses-and-projects
AstraZeneca and MRC Laboratory of Molecular Biology to launch joint research fund
http://www.pharmanews.eu/astrazeneca/1444-astrazeneca-and-mrc-laboratory-of-molecular-biology-to-launch-joint-research-fund
Shark antibodies inspire optimization of human antibodies
http://www.pharmanews.eu/research-and-development/1442-shark-antibodies-inspire-optimization-of-human-antibodies
New agent may enhance effectiveness of radiotherapy
http://www.pharmanews.eu/research-and-development/1443-new-agent-may-enhance-effectiveness-of-radiotherapy
Atlas shows how genes affect our metabolism
http://www.pharmanews.eu/research-and-development/1440-atlas-shows-how-genes-affect-our-metabolism
CNIO team presents a new strategy to personalise cancer therapies
http://www.pharmanews.eu/research-and-development/1441-cnio-team-presents-a-new-strategy-to-personalise-cancer-therapies
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
The first preclinical study of a new Rice University-developed anti-cancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells - often by blowing them apart - without harming surrounding normal organs. The research, which is available online this week Nature Medicine, reports that Rice's "quadrapeutics" technology was 17 times more efficient than conventional chemoradiation therapy against aggressive, drug-resistant head and neck tumors.
Read more...
http://www.worldpharmanews.com/research/2790-quadrapeutics-works-in-preclinical-study-of-hard-to-treat-tumors
Pfizer and the Avon Foundation for Women announce $1 million grants program
Despite the high level of public attention devoted to breast cancer awareness, more than 60 percent of respondents in a new national survey commissioned by Pfizer Inc. say they know little to nothing about metastatic breast cancer.(1) The survey is the first of its kind to examine the general public's understanding of metastatic breast cancer, which affects up to 250,000 women and men in the U.S. today.(2)
Read more...
http://www.worldpharmanews.com/pfizer/2789-pfizer-and-the-avon-foundation-for-women-announce-1-million-grants-program
Understanding and overcoming a novel type of anticancer drug resistance
A mechanism that enables the development of resistance to Acute Myeloid Leukemia (AML) anticancer drugs, thereby leading to relapse, has been identified by Katherine Borden of the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) and her collaborators. Katherine Borden is a Principal Investigator at IRIC and a professor at the university's Department of Pathology and Cell Biology.
Read more...
http://www.worldpharmanews.com/research/2788-understanding-and-overcoming-a-novel-type-of-anticancer-drug-resistance
Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS
In support of World MS Day, Novartis announced today the launch of the 7-Day Challenge to Live Like You for people with MS. The 7-Day Challenge to Live Like You, one of the first integrations of emerging technological trends by a pharmaceutical company, is simple: using wearable technology or accessing personal online systems that people use on a daily basis, including calendars, social media channels and fitness trackers, people with MS are invited to track their activities for seven days and gain valuable insights into what works best for their lifestyle.
Read more...
http://www.worldpharmanews.com/novartis/2787-novartis-launches-7-day-challenge-to-live-like-you-enabling-people-with-ms-to-better-understand-their-lives-with-ms
FDA approves many drugs that predictably increase heart and stroke risk
The agency charged to protect patients from dangerous drug side effects needs to be far more vigilant when it comes to medications that affect blood pressure. Robert P. Blankfield, MD, MS, a clinical professor of family medicine, issues this call to the U.S. Food and Drug Administration (FDA) in an editorial published recently in an online edition of the Journal of Cardiovascular Pharmacology and Therapeutics; the print version of the article is expected to appear this autumn.
Read more...
http://www.worldpharmanews.com/research/2786-fda-approves-many-drugs-that-predictably-increase-heart-and-stroke-risk
Pfizer brings frequent heartburn relief OTC with new Nexium® 24HR
Pfizer Inc. (NYSE: PFE) has announced the introduction in the U.S. of over-the-counter (OTC) Nexium®24HR, making The Purple Pill® available for the treatment of frequent heartburn (two or more days a week) in adults (18 years and older). Heartburn affects more than 60 million men and women in the United States at least once a month with 15 million Americans suffering from it daily.(1)
Read more...
http://www.worldpharmanews.com/pfizer/2785-pfizer-brings-frequent-heartburn-relief-otc-with-new-nexiumr-24hr
New way to treat HER2-positive breast cancer
Scientists at Cold Spring Harbor Laboratory (CSHL) have reported a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer. The breast cancer subtype in question is commonly called "HER2-positive"; it's a subset of the disease affecting about one patient in four, in which tumor cells overexpress a signaling protein called HER2.
Read more...
http://www.worldpharmanews.com/research/2784-new-way-to-treat-her2-positive-breast-cancer
PharmaNews.eu / Latest News
Finnish researchers discovered a new anticancer compound using accelerated drug screening process
http://www.pharmanews.eu/research-and-development/1446-finnish-researchers-discovered-a-new-anticancer-compound-using-accelerated-drug-screening-process
Biovision presents its selection of 44 promising life sciences businesses and projects
http://www.pharmanews.eu/conferences-and-events/1445-biovision-presents-its-selection-of-44-promising-life-sciences-businesses-and-projects
AstraZeneca and MRC Laboratory of Molecular Biology to launch joint research fund
http://www.pharmanews.eu/astrazeneca/1444-astrazeneca-and-mrc-laboratory-of-molecular-biology-to-launch-joint-research-fund
Shark antibodies inspire optimization of human antibodies
http://www.pharmanews.eu/research-and-development/1442-shark-antibodies-inspire-optimization-of-human-antibodies
New agent may enhance effectiveness of radiotherapy
http://www.pharmanews.eu/research-and-development/1443-new-agent-may-enhance-effectiveness-of-radiotherapy
Atlas shows how genes affect our metabolism
http://www.pharmanews.eu/research-and-development/1440-atlas-shows-how-genes-affect-our-metabolism
CNIO team presents a new strategy to personalise cancer therapies
http://www.pharmanews.eu/research-and-development/1441-cnio-team-presents-a-new-strategy-to-personalise-cancer-therapies
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages